Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...

Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...

Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.

Dimerix Limited ( ($AU:DXB) ) has provided an update. Dimerix Limited has announced the quotation of 147,275 ordinary fully paid securities on the ...

In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Healthcare analysts believe that shares in rare neurological share play Neuren Pharmaceuticals are well undervalued after a ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX ...

Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.